--- title: "Akeso lung cancer drug cuts death risk 34% in landmark trial" url: https://daily.dev/posts/akeso-lung-cancer-drug-cuts-death-risk-34-in-landmark-trial-an1i7ejqn source_url: https://thenextweb.com/news/akeso-ivonescimab-lung-cancer-asco-china-biotech type: article source: "The Next Web" published: 2026-06-01T14:46:38.349Z updated: 2026-06-01T14:47:06.708Z tags: ["biotech"] reading_time: 4 upvotes: 0 comments: 0 language: en --- > ## Documentation Index > Fetch the complete documentation index at: https://daily.dev/llms.txt > Use this file to discover all available pages before exploring further. # Akeso lung cancer drug cuts death risk 34% in landmark trial **[The Next Web](https://daily.dev/sources/tnw)** · 4 min read · 0 upvotes · 0 comments ## Summary Akeso's bispecific antibody ivonescimab has shown a 34% reduction in death risk for advanced squamous non-small cell lung cancer patients in the phase three HARMONi-6 trial. Patients on ivonescimab plus chemotherapy survived a median 27.9 months versus 23.7 months on the current standard therapy (tislelizumab plus chemotherapy), with 64.7% alive at two years compared to 48.6% in the control group. The results earned a spot at ASCO's plenary session — the first Chinese-originated oncology drug to do so in 61 years. Summit Therapeutics holds exclusive US/EU/Canada/Japan rights and has filed a BLA with the FDA, with a target action date of November 2026. The trial positions ivonescimab to compete in a $20B+ NSCLC market and signals China's biotech industry maturing from generics to globally competitive innovative drugs. ## Full article daily.dev links to this article rather than hosting it. Read it at the original source: ## Similar posts on daily.dev - [A new immunotherapy approach could work for many types of cancer](https://daily.dev/posts/a-new-immunotherapy-approach-could-work-for-many-types-of-cancer-aok1n6y0z) · MIT News · 1 upvotes · 0 comments - [A new approach to cancer vaccination yields more powerful T cells](https://daily.dev/posts/a-new-approach-to-cancer-vaccination-yields-more-powerful-t-cells-cpohvm6nf) · MIT News · 0 upvotes · 0 comments - [Bristol Myers Squibb signs $15.2 billion drug deal with China's Hengrui as patent cliff looms](https://daily.dev/posts/bristol-myers-squibb-signs-15-2-billion-drug-deal-with-china-s-hengrui-as-patent-cliff-looms-dvilzff3j) · The Next Web · 0 upvotes · 0 comments --- Tags: [#biotech](https://daily.dev/tags/biotech) [View this post on daily.dev](https://daily.dev/posts/akeso-lung-cancer-drug-cuts-death-risk-34-in-landmark-trial-an1i7ejqn)